Behçet disease (BD) is a relapsing inflammatory disorder characterized by mucocutaneous ulcers 9both oral and genital) and often involves the neurological, ophthalmological, musculoskeletal, gastrointestinal and vascular systems. While the of BD is not yet known, its features are thought to be related to an underlying systemic vasculitis. Research that focuses on the immunological phenomena that drive this disease aims to better understand current treatments and uncover new therapies. With recent data suggesting that biologics may be beneficial in managing the life-threatening complications of BD, particularly its vascular complications, there is increasing evidence to support the use of biologics, including the TNF-a inhibitors, as first-line therapy.